Randomized Phase III Study Comparing an Early PET Driven Treatment De Escalation to a Not PET-Monitored Strategy in Patients with Advanced Stages Hodgkin Lymphoma: Interim Analysis of the AHL2011 Lysa Study

被引：0

作者：

Casasnovas, Olivier ^{[1
]}

Brice, Pauline ^{[2
,23
]}

Bouabdallah, Reda ^{[3
]}

Salles, Gilles A. ^{[4
]}

Stamatoullas, Aspasia ^{[5
]}

Dupuis, Jehan ^{[6
]}

Reman, Oumedaly ^{[7
]}

Gastinne, Thomas ^{[8
]}

Joly, Bertrand ^{[9
]}

Bouabdallah, Krimo ^{[10
]}

Nicolas-Virelizier, Emmanuelle ^{[11
]}

Bologna, Serge ^{[12
]}

Morschhauser, Franck ^{[13
]}

Delarue, Richard ^{[14
]}

Farhat, Hassan ^{[15
]}

Quittet, Philippe ^{[16
]}

Berriolo-Riedinger, Alina ^{[17
]}

Tempescul, Adrian ^{[18
]}

Edeline, Veronique ^{[19
]}

Maisonneuve, Herve ^{[20
]}

Eisenmann, Jean Claude ^{[21
]}

Traverse-Glehen, Alexandra ^{[22
]}

Andre, Marc ^{[23
]}

Mounier, Nicolas ^{[24
]}

Meignan, Michel ^{[25
]}

Ferme, Christophe ^{[26
]}

机构：

[1] CHU Dijon, Hop Le Bocage, Dept Hematol, Dijon, France

[2] Hop St Louis, APHP, Hematol, Paris, France

[3] Inst J Paoli I Calmettes, Dept Hematol, Lymphoma Program, F-13009 Marseille, France

[4] Univ Lyon 1, Hosp Civils Lyon, Pierre Benite, France

[5] Ctr Henri Becquerel, Clin Hematol, F-76038 Rouen, France

[6] Grp Hosp Mondor, APHP, Lymphoid Malignancies Unit, Creteil, France

[7] CHU Caen, Hematol, F-14000 Caen, France

[8] CHU Nantes, Dept Hematol, F-44035 Nantes 01, France

[9] Ctr Hosp Sud Francilien, Dept Hematol, Corbeil Essonnes, France

[10] CHU Bordeaux, Bordeaux, France

[11] Ctr L Berard, Dept Hematol, Lyon, France

[12] CHU Nancy, Dept Hematol, Vandoeuvre Les Nancy, France

[13] Univ Lille 2, Ctr Hosp Univ, Hematol, Lille, France

[14] Hop Necker Enfants Malad, AP HP, Hematol, Paris, France

[15] CH Versailles, Dept Hematol, Versailles, France

[16] CHU St Eloi Montpellier, Dept Hematol, Montpellier, France

[17] Ctr GF Leclerc, Dept Nucl Med, Dijon, France

[18] CHU Brest, Hematol Dept, F-29285 Brest, France

[19] Inst Curie, Dept Nucl Med, Paris, France

[20] CH, Dept Hematol & Oncol, La Roche Sur Yon, France

[21] CH Mulhouse, Dept Hematol, Mulhouse, France

[22] Univ Lyon 1, Hosp Civils Lyon, Dept Pathol & Hematol, F-69365 Lyon, France

[23] CHU Dinant Godinne, Dept Hematol, Yvoir, Belgium

[24] Hop LArchet, CHU Nice, Dept Hematol, Nice, France

[25] Grp Hosp Mondor, AP HP, Nucl Med, Creteil, France

[26] Inst Gustave Roussy, Dept Hematol, Villejuif, France

来源：

BLOOD | 2015年 / 126卷 / 23期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 46 条

[1] Randomized Phase III Study Comparing an Early PET-Driven Treatment De-Escalation to a Not PET-Monitored Strategy in Patients With Advanced-Stages Hodgkin Lymphoma: Final Analysis of the AHL2011 LYSA Study
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (08) : 9 - 11
[2] Randomized phase III study comparing an early PET driven treatment deescalation to a not PET-monitored strategy in patients with advanced stages Hodgkin lymphoma: Final analysis of the AHL2011 LYSA study.
Casasnovas, Olivier
Brice, Pauline
Bouabdallah, Reda
Salles, Gilles A.
Stamatoulas, Aspasia
Dupuis, Jehan
Reman, Oumedaly
Gastinne, Thomas
Joly, Bertrand
Bouabdallah, Kamal
Nicolas-Virelizier, Emmanuelle
Feugier, Pierre
Morschhauser, Franck
Delarue, Richard
Berriolo-Riedinger, Alina
Edeline, Veronique
Traverse-Glehen, Alexandra
Andre, Marc
Mounier, Nicolas
Meignan, Michel
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[3] Gonadal Function Recovery in Patients With Advanced Hodgkin Lymphoma Treated With a PET-Adapted Regimen: Prospective Analysis of a Randomized Phase III Trial (AHL2011)
Demeestere, Isabelle
Racape, Judith
Dechene, Julie
Dupuis, Jehan
Morschhauser, Franck
De Wilde, Virginie
Lazarovici, Julien
Ghesquieres, Herve
Touati, Mohamed
Sibon, David
Alexis, Magda
Gac, Anne-Claire
Moatti, Hannah
Virelizier, Emmanuelle
Maisonneuve, Herve
Pranger, Delphine
Houot, Roch
Fornecker, Luc-Matthieu
Tempescul, Adrian
Andre, Marc
Casasnovas, Rene-Olivier
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (29) : 3251 - +
[4] Positron Emission Tomography-Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study
Casasnovas, Rene-Olivier
Bouabdallah, Reda
Brice, Pauline
Lazarovici, Julien
Ghesquieres, Herve
Stamatoullas, Aspasia
Dupuis, Jehan
Gac, Anne-Claire
Gastinne, Thomas
Joly, Bertrand
Bouabdallah, Krimo
Nicolas-Virelizier, Emmanuelle
Feugier, Pierre
Morschhauser, Franck
Sibon, David
Bonnet, Christophe
Berriolo-Riedinger, Alina
Edeline, Veronique
Parrens, Marie
Damotte, Diane
Coso, Diane
Andre, Marc
Meignan, Michel
Rossi, Cedric
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (10) : 1091 - +
[5] AHL 2011: A Lysa randomized phase III study of a treatment driven by early PET response compared to a standard treatment in patients with Ann Arbor stage III-IV or high-risk IIB Hodgkin lymphoma.
Casasnovas, Rene-Olivier
Meignan, Michel
Reman, Oumedaly
Gaillard, Isabelle
Stamatoullas, Aspasia
Brice, Pauline
Salles, Gilles A.
Bouabdallah, Reda
Bologna, Serge
Nicolas-Virelizier, Emmanuelle
Morschhauser, Franck
Janvier, Maud
Andre, Marc
Berriolo-Riedinger, Alina
Traverse-Glehen, Alexandra
Edeline, Veronique
Dartigues, Peggy
Parrens, Marie
Mounier, Nicolas
Ferme, Christophe
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[6] PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study
Casasnovas, Rene-Olivier
Bouabdallah, Reda
Brice, Pauline
Lazarovici, Julien
Ghesquieres, Herve
Stamatoullas, Aspasia
Dupuis, Jehan
Gac, Anne-Claire
Gastinne, Thomas
Joly, Bertrand
Bouabdallah, Krimo
Nicolas-Virelizier, Emmanuelle
Feugier, Pierre
Morschhauser, Franck
Delarue, Richard
Farhat, Hassan
Quittet, Philippe
Berriolo-Riedinger, Alina
Ternpescul, Adrian
Edeline, Veronique
Maisonneuve, Nerve
Fomecker, Luc-Matthieu
Lamy, Thiery
Delmer, Alain
Dartigues, Peggy
Martin, Laurent
Andre, Marc
Moonier, Nicolas
Traverse-Glehen, Alexandra
Meignan, Michel
LANCET ONCOLOGY, 2019, 20 (02): : 202 - 215
[7] PET-Guided Strategy Improves the Safety of Beacopp-Based Treatment in Advanced Hodgkin Lymphoma: Prolonged Follow-up of the Lysa Ahl 2011 Phase 3 Study
Casasnovas, Olivier
Racape, Judith
Dechene, Julie
Bouabdallah, Reda
Brice, Pauline
Lazarovici, Julien
Ghesquieres, Herve
Bastard, Aspasia Stamatoulas
Dupuis, Jehan
Gac, Anne-Claire
Gastinne, Thomas
Joly, Bertrand
Bouabdallah, Krimo
Nicolas-Virelizier, Emmanuelle
Feugier, Pierre
Morschhauser, Franck
Andre, Marc
Berriolo-Riedinger, Alina
Edeline, Veronique
Joubert, Clementine
Meignan, Michel
Demeestere, Isabelle
BLOOD, 2020, 136
[8] PET-Guided Strategy Improves the Safety of BEACOPP-Based Treatment in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the Lysa AHL 2011 Phase 3 Study
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (02) : 17 - 19
[9] Ovarian function recovery in newly diagnosed advanced Hodgkin lymphoma patients treated with PET-adapted regimen: prospective analysis of a mu Iticentric randomized phase 3 trial (AHL2011)
Demeestere, I.
Dechene, J.
Racape, J.
Bouabdallah, R.
Brice, P.
Ghesquieres, H.
Stamatoulas, A.
Dupuisl, J.
Gac, A. G.
Gastinne, T.
Joly', B.
Bouabdallah, K.
Casasnovas, O., I
HUMAN REPRODUCTION, 2020, 35 : 17 - 18
[10] The Combination of High Expression of CD68-Positive Tumor-Associated Macrophages and PET2-Positivity Predicts Unfavorable Outcome in Patients with Classical Hodgkin Lymphoma Treated in the Lysa AHL2011 Study
Traverse-Glehen, Alexandra
Damotte, Diane
Dartigues, Peggy
Martin, Laurent
Parrens, Marie
Guesquieres, Herve
Sarkozy, Clementine
Deau, Benedicte
Bouabdallah, Reda
Garciaz, Sylvain
Meignan, Michel
Edeline, Veronique
Kanoun, Salim
Berriolo-Riedinger, Alina
Brice, Pauline
Rossi, Cedric
Stamatoullas, Aspasia
Veillard, Anne Sophie
Andre, Marc
Casasnovas, Olivier
BLOOD, 2016, 128 (22)

← 1 2 3 4 5 →